Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

Korea / Special Sits, Pairs, Index Rebalancing

Equity Capital Markets

Applied Surface Technology / Equity Capital Markets

ASTA (Applied Surface Technology) (established in 2006) submitted the IPO report. ASTA is a technology-based company that develops and manufactures analytical instruments, equipment for sample preparations, and supplies. In particular, ASTA focuses on the development of MALDI-TOF MS (Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometer), its applications and supplies including MALDI-plates, matrix spotter and microwave based sample digestion system. Recently, MALDI-TOF has been introduced and widely used in the medical field as a diagnostic technology. ASTA has been developing various MALDI-TOF based medical applications such as cancer diagnosis and micro-organism identification. The glycan pattern analysis of serum proteins by MALDI-TOF, which is a ASTA owned cutting-edge technology, has successfully applied to early diagnosis of ovarian cancer and expanding its applications to other cancers such as breast cancer. In addition, MALDI-TOF based micro-organism identification system has been launched by ASTA and expanding its usages to medical field, agricultural industry and food industry etc.* In Part 1 (as below), I summarized the overview of this IPO with the financials and valuation. In Part 2, I will analyze the company's growth potential and appropriate valuation level.

ASTA (Applied Surface Technology) (established in 2006) submitted the IPO report. ASTA is a technology-based company that develops and manufactures analytical instruments, equipment for sample preparations, and supplies. In particular, ASTA focuses on the development of MALDI-TOF MS (Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometer), its applications and supplies including MALDI-plates, matrix spotter and microwave based sample digestion system. Recently, MALDI-TOF has been introduced and widely used in the medical field as a diagnostic technology. ASTA has been developing various MALDI-TOF based medical applications such as cancer diagnosis and micro-organism identification. The glycan pattern analysis of serum proteins by MALDI-TOF, which is a ASTA owned cutting-edge technology, has successfully applied to early diagnosis of ovarian cancer and expanding its applications to other cancers such as breast cancer. In addition, MALDI-TOF based micro-organism identification system has been launched by ASTA and expanding its usages to medical field, agricultural industry and food industry etc.* In Part 1 (as below), I summarized the overview of this IPO with the financials and valuation. In Part 2, I will analyze the company's growth potential and appropriate valuation level.

ASTA IPO Part 1 - Schedule, Financials & Valuation

Thematic (Sector/Industry)

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

South Korea

Macrogen Inc. provides DNA sequencing and genome research services.  The Company also raises and sells transgenic and knockout mice to biotechnology institutes and pharmaceutical companies.  Macrogen develops DNA chips, which are used to improve the diagnosis and treatment of disease as well.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Macrogen Inc (038290 KS)

ASTA IPO Part 1 - Schedule, Financials & Valuation

ASTA (Applied Surface Technology) (established in 2006) submitted the IPO report. ASTA is a technology-based company that develops and manufactures...

Sanghyun Park

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)